Function of REIC/Dkk-3, a putative Wntregulator in normal skin and cancer
Function of REIC/Dkk-3, a putative Wntregulator in normal skin and cancer
批准号:
18591249
负责人:
KATAOKA Ken
金额:
$2.24万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2006
资助国家:
日本
项目状态:
已结题
起止时间:
2006 至 2007
中文摘要
1.筛选携带ReIC/DKK-3的重组腺病毒(Ad-ReIC)感染正常人角质形成细胞后表达上调的基因,结果表明该细胞因子具有较强的诱导性。通过体外和体内实验,我们得出结论:Ad-reic治疗通过体内的细胞因子激活了对癌细胞的免疫反应。当使用Ad-REIC过表达时,REIC/DKK-3可诱导癌细胞凋亡,但不能诱导正常细胞。阿德瑞克对人前列腺癌(PC3)、睾丸癌(NCCIT)和小鼠肾癌(RencA)均有效,但并不是所有肿瘤都对阿德瑞克敏感。为了了解腺病毒敏感性的重要机制,我们比较了腺病毒敏感的肾癌细胞(RECA)和正常成纤维细胞(N1H3T3)。我们发现Hsp70/72的表达水平影响Ad-REIC对肿瘤细胞的特异性诱导凋亡。我们从一株前列腺癌细胞系(PC3)中建立了Adreic耐药亚系。一项概述这些基因表达谱的微阵列分析正在进行中。通过比较Adreic处理后的内质网应激反应,我们发现了一个与Adreic敏感性有关的关键分子。我们还建立了一种从人成纤维细胞中纯化REIC/DKK-3蛋白的方法。我们正在比较添加这种类型的纯化蛋白和通过Ad-REIC5强制表达系统。新一代REIC/DKK-3基因敲除小鼠正在研究中。我们已经得到了敲除的ES细胞,我们正在等待嵌合体的分生。
英文摘要
1. The screening of genes which expression level were elevated after the infection of an adenovirus canying REIC/Dkk-3 (Ad-REIC) into normal human keratinocytes showed that a specific cytokine was strongly induced. After in vitro and in vivo experiments, we conclude that Ad-REIC treatment activates immune reaction against cancer cells through the cytokine in vivo.2. When over expressed using Ad-REIC, REIC/Dkk-3 induced apoptosisin cancer cells but not in normal cells. Ad-REIC was effective on human prostate cancer (PC3), testicular cancer (NCCIT) and mouse renal carcinoma (RENCA), but not all cancers are sensitive to Ad-REIC. To know the crucial mechanism of Ad-REIC sensitivity, we compared Ad-REIC sensitive renal cancer cells (RENCA) with normal fibroblast (N1H3T3). We found that the expression level of Hsp70/72 affected on tumor-cell specific induction of apoptosis by Ad-REIC.3. We established Ad-REIC-resistant sub-lines from a prostate cancer cell line (PC3). A micro array analysis to overview the expression profile of these lines is on the way. After the comparison of ER stress response after Ad-REIC treatment, we found a key molecule to be responsible for the Ad-REIC sensitivity.4. We also established a method for the purification of REIC/Dkk-3 protein from human fibroblasts. We are comparing addition of this type of purified protein with forced expression system by Ad-REIC.5. Generation of REIC/Dkk-3 knockout mouse is under way. We already got knockout ES cells and we are waiting chimera littermates.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.3892/ijmm.20.1.37
发表时间:
2007-07
期刊:
International journal of molecular medicine
影响因子:
5.4
作者:
[F. Abarzúa;M. Sakaguchi;R. Tanimoto;Hiroyuki Sonegawa;Dai Li;K. Edamura;Tomoko Kobayashi;Masami Watanabe;Y. Kashiwakura;H. Kaku;T. Saika;K. Nakamura;Y. Nasu;H. Kumon;N. Huh]
通讯作者:
F. Abarzúa;M. Sakaguchi;R. Tanimoto;Hiroyuki Sonegawa;Dai Li;K. Edamura;Tomoko Kobayashi;Masami Watanabe;Y. Kashiwakura;H. Kaku;T. Saika;K. Nakamura;Y. Nasu;H. Kumon;N. Huh
DOI:
10.1007/s00109-007-0180-7
发表时间:
2007-05
期刊:
Journal of Molecular Medicine
影响因子:
--
作者:
[Hiroyuki Sonegawa;T. Nukui;Dai Li;M. Takaishi;M. Sakaguchi;N. Huh]
通讯作者:
Hiroyuki Sonegawa;T. Nukui;Dai Li;M. Takaishi;M. Sakaguchi;N. Huh
S100A11, a Dual Mediator for Growth Regulation of Human Keratinocytes
S100A11,人类角质形成细胞生长调节的双重介质
DOI:
--
发表时间:
2008
期刊:
Mol Biol Cell 19
影响因子:
--
作者:
[Sakaguchi, et. al.]
通讯作者:
et. al.
Truncation of annexin Al is a regulatory lever for linking epidermal growth factor signaling with cytosolic phospholipase A2 in normal and malignant squamous epithelial cells
膜联蛋白A1的截短是连接正常和恶性鳞状上皮细胞中表皮生长因子信号转导与胞质磷脂酶A2的调节杠杆
DOI:
--
发表时间:
2007
期刊:
J Biol Chem 282
影响因子:
--
作者:
[Sakaguchi, et. al.]
通讯作者:
et. al.
DOI:
10.1038/sj.cgt.7701071
发表时间:
2007-09-01
期刊:
CANCER GENE THERAPY
影响因子:
6.4
作者:
[Edamura, K., Nasu, Y., Kumon, H.]
通讯作者:
Kumon, H.
共 11 条
New combinatorial approach to peritoneal dissemination of scirrhous gastric carcinoma based REIC/Dkk-3 gene therapy
-
批准号:21591699
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.66万
-
财政年份:2009
-
负责人:KATAOKA Ken
-
依托单位:
国内基金
海外基金
DNA甲基化修饰Wif-1和Dkk-3调控Wnt通路在肝纤维化发生中的作用机制研究
-
批准号:81100303
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2011
-
负责人:吕瑞雪
-
依托单位: